tiprankstipranks
The United Laboratories International Holdings Limited (HK:3933)
HKEX:3933

The United Laboratories International Holdings (3933) Stock Price & Analysis

0 Followers

3933 Stock Chart & Stats

Day’s RangeHK$0 - HK$0
52-Week RangeHK$5.59 - HK$10.24
Previous CloseHK$9.59
Volume2.23M
Average Volume (3M)4.07M
Market Cap
HK$17.39B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)5.8
Beta0.71
Aug 27, 2024
Dividend Yield3.66%
Share Statistics
EPS (TTM)1.64
Shares OutstandingN/A
10 Day Avg. Volume4,905,000
30 Day Avg. Volume4,074,731
Standard Deviation0.12
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside60.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2

Options Prices

Currently, No data available
---

Ownership Overview

0.00%4.81%2.75%92.44%
0.00%
Insiders
2.75% Other Institutional Investors
92.44% Public Companies and
Individual Investors

3933 FAQ

What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$5.59 and its highest was HK$10.24 in the past 12 months.
    What is The United Laboratories International Holdings Limited’s market cap?
    Currently, no data Available
    When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
    The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2024 which is in 129 days.
      How were The United Laboratories International Holdings Limited’s earnings last quarter?
      The United Laboratories International Holdings Limited released its earnings results on Mar 25, 2024. The company reported HK$0.844 earnings per share for the quarter, beating the consensus estimate of HK$0.776 by HK$0.068.
        Is The United Laboratories International Holdings Limited overvalued?
        According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does The United Laboratories International Holdings Limited pay dividends?
          The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 3.66%. See more information on The United Laboratories International Holdings Limited dividends here
            What is The United Laboratories International Holdings Limited’s EPS estimate?
            The United Laboratories International Holdings Limited’s EPS estimate is HK$0.7.
              How many shares outstanding does The United Laboratories International Holdings Limited have?
              The United Laboratories International Holdings Limited has 1,817,026,500 shares outstanding.
                What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
                The United Laboratories International Holdings Limited reported an EPS of HK$0.844 in its last earnings report, beating expectations of HK$0.776. Following the earnings report the stock price went up 0.831%.
                  Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
                  Currently, no hedge funds are holding shares in HK:3933
                  ---

                  The United Laboratories International Holdings Stock Smart Score

                  10
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  The United Laboratories International Holdings Limited

                  United Laboratories International Holdings Ltd. operates as an investment company, which engages in the manufacturing and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA. The Bulk Medicine segment includes amoxicillin and insulin. The Finished Products segment includes the sale of antibiotics and non-antibiotics finished products, and capsule casings including Semi-synthetic penicillins antibiotics, Cephalosporins antibiotics, and Insulin products. The company was founded on March 6, 2006 and is headquartered in Hong Kong.
                  ---

                  3933 Stock 12 Months Forecast

                  Average Price Target

                  HK$15.43
                  ▲(60.87% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"HK$5","22":"HK$22","9.25":"HK$9.25","13.5":"HK$13.5","17.75":"HK$17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.99999914343,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.4277595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$15.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.92999965231045,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$8.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.2,10.184615318725385,11.169230637450768,12.153845956176154,13.138461274901537,14.123076593626923,15.107691912352308,16.09230723107769,17.076922549803076,18.06153786852846,19.046153187253847,20.030768505979232,21.015383824704614,{"y":21.99999914343,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.2,9.679058423076922,10.158116846153845,10.637175269230768,11.116233692307691,11.595292115384614,12.074350538461537,12.553408961538462,13.032467384615384,13.511525807692308,13.99058423076923,14.469642653846154,14.948701076923077,{"y":15.4277595,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.2,9.17923074248542,9.158461484970838,9.137692227456258,9.116922969941676,9.096153712427096,9.075384454912514,9.054615197397935,9.033845939883353,9.013076682368773,8.992307424854191,8.971538167339611,8.95076890982503,{"y":8.92999965231045,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.095,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.636,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.209,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.022,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.749,"date":1692316800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.887,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1708041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  The United Laboratories International Holdings
                  Pfizer
                  Merck & Company
                  GlaxoSmithKline
                  AbbVie

                  Best Analysts Covering 3933

                  1 Year
                  Chris LuiJefferies
                  1 Year Success Rate
                  5/5 ratings generated profit
                  100%
                  1 Year Average Return
                  +21.48%
                  reiterated a buy rating 16 days ago
                  Copying Chris Lui's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.48% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis